EA8212 : A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Principal Investigator
Study Number
STUDY02002062
Summary
This study is for people with high-risk non-muscle-invasive bladder cancer (NMIBC). Researchers are comparing the usual treatment, intravesical BCG (Bacillus Calmette Guerin) and chemotherapy drugs (docetaxel and gemcitabine) for high-risk non-muscle-invasive bladder cancer. Participants will be randomly assigned to either treatment, and the researchers aim to compare cancer recurrence rates and quality of life between the two groups.
Phase
III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms